About Us

CAMBRIDGE, England. – May 14, 2021
Abcodia, a clinical stage company engaged in the commercial development of novel tests for the early detection of cancer, acknowledges the results from UCL reporting that the large-scale randomised trial of annual screening for ovarian cancer did not succeed in reducing deaths from the disease. (LINK Screening for ovarian cancer did not reduce deaths | MRC Clinical Trials Unit at UCL)

Results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) have been published in a report in the medical journal The Lancet. (LINK Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial – The Lancet)

Julie Barnes, CEO of Abcodia, said: “It is disappointing that such a promising public health approach that had potential to reduce mortality from ovarian cancer, and offered hope for a population-based screening programme for post-menopausal women, has not resulted in a positive outcome. This is despite evidence that screening can detect more earlier stage disease. UKCTOCS was an important UK-funded study that has taken years of dedication and diligence, and it has made an important contribution to the understanding of ovarian cancer.”

MEDIA CONTACT

Sue Charles
Charles Consultants
T: +44 (0)7968 726585
E: sue.charles59@outlook.com